Please login to the form below

Not currently logged in
Email:
Password:

Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales. Drug shown to reduce major adverse cardiovascular events. ... Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    Novartis' Ilaris wins three new FDA approvals. Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. ... Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU

  • Novartis lifts 2013 guidance on delay to Diovan generics Novartis lifts 2013 guidance on delay to Diovan generics

    Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... The new SJIA indication will add further momentum to Ilaris, which grew 56 per cent last year to reach $72m in sales.

  • Novartis' Ilaris cleared for gouty arthritis in EU Novartis' Ilaris cleared for gouty arthritis in EU

    Novartis' Ilaris cleared for gouty arthritis in EU. First biologic drug approved for condition in Europe. ... Ilaris was launched in the US and EU in 2009 as a treatment for an auto-inflammatory condition called cryopyrin-associated periodic syndrome

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics